Recent advancements in the treatment of chronic myelogenous leukemia

Annu Rev Med. 2002:53:369-81. doi: 10.1146/annurev.med.53.082901.103853.

Abstract

Chronic myelogenous leukemia (CML) is a clonal hematopoetic stem cell disorder characterized by the Philadelphia chromosome and resultant production of the constitutively activated Bcr-Abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem cell transplantation, with stem cell transplantation being the only curative therapy. Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Enzyme Activation
  • Fusion Proteins, bcr-abl
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Imatinib Mesylate
  • Interferons / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Piperazines / therapeutic use
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / genetics
  • Pyrimidines / therapeutic use

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Interferons
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl